Microbiotica
Clinical-stage precision microbiome medicines for ulcerative colitis and cancer
About
Microbiotica is a clinical-stage biopharma company near Cambridge, UK, spun out of the Wellcome Sanger Institute in 2016, developing orally dosed live biotherapeutic products. Its genomics-driven platform combines a gut microbiome culture collection, a proprietary reference genome database, bioinformatics and machine learning to identify bacteria associated with favourable clinical trial outcomes. Lead programme MB310, an eight-strain once-daily oral therapy for ulcerative colitis, met its Phase 1b endpoints, and MB097 is being developed with KEYTRUDA for advanced melanoma. On 16 October 2026 Microbiotica announced a £36 million ($48 million) Series C first close led by British Business Bank with Tencent, IP Group, Cambridge Innovation Capital, Flerie Invest and Seventure Partners to take MB310 into Phase 2.
- Website
- microbiotica.com
- Stage
- series-b+
- Location
- Cambridge, United Kingdom
- Added via
- web
- Ownership
- unclaimed
Where to go
For people
- Homepagemicrobiotica.com
- Press releasesmicrobiotica.com/press-releases
- Working heremicrobiotica.com/working-here
- Pipelinemicrobiotica.com/pipeline
- Platformmicrobiotica.com/platform
For agents
Nothing listed yet.